Table 6 Recent updates on CAR-T cell therapy for multiple myeloma
Ide-Cel (bb2121) (KarMMA) | bb21217 (CRB-402) | Cilta-Cel (CARTITUDE-1) | CT053 (LUMMICAR-2) | Orva-Cel (EVOLVE) | FasT (GC012F) | P-BCMA-101 (PRIME) | Universal ALLO-715 | |
|---|---|---|---|---|---|---|---|---|
Phase | 2 | 1 | 1b/2 | 1b/2 | 1/2 | 1 | 1/2 | 1 |
Patients (n) | 128 | 46 | 97 | 14 | 44 | 16 | 43 | 15 |
Target | BCMA | BCMA with PI3Ki bb007 | 2-epitope BCMA | BCMA | BCMA | Dual BCMA-CD19 | BCMA | BCMA |
ORR/CR/MRD | 73%/33%/26% | 55%/18%/NA | 95%/56%(sCR)/94.2% | 100%/29%/92% | 91%/39%/84% | 93.8%/NA/56.3% | 57%/NA/NA | 33%/NA/NA |
Median PFS (month) | 8.8mo | NA | Not reached | NA | NA | NA | NA | NA |
Median OS (month) | 19.4mo | NA | Not reached | NA | NA | NA | NA | NA |
CRS, any grade | 84% | 67% | 94.8% | 86% | NA | 87.5% | 17% | 24% |
CRS, > = grade3 | 5% | 4% (one grade 5) | 4.1% | 0% | 2% | 12.5% | 2% | 0% |
Neurotoxicity, any grade | 18% | 22% | 20.6% | 7% | NA | 0% | 2% | 0% |
Neurotoxicity, > = grade3 | 3% | 7% | 10.3% | 0% | 4% | 0% | 0% | 0% |
Reference | [54] NEJM 2021 | [57] ASH 2020 #653 | [55] ASH 2020 #177 | [56] ASH 2020 #133 | [58] ASCO 2020 #8504 | [61] ASH 2020 #178 | [59] ASH 2020 #134 | [62] ASH 2020 #129 |